Immunotherapy for Gynecology-Oncology Malignancies: Is There Still Time for Progress?
Oladap O. Yeku, MD, PhD, FACP
Changing Delivery of Chemotherapy for Breast Cancer: The Era of Antibody Drug Conjugates
Wassim Mchayleh, MD, FACP, MBA
Optimal Treatment for Early Stage HER2 Positive Breast Cancer: Tailoring Treatment to Response
Luis Baez Vallecillo, MD
Sequencing Endocrine Therapy and Targeted Agents for the Treatment of Metastatic HR+/HER2- Breast Cancer
Noridza Rodriguez-Rivera, MD
The Challenges of Biosimilars in the Daily Oncology Practice?
Dina B. Dumercy McHenry, PharmD, MBA, BCOP
Treating Advanced Or Metastatic Cervical Cancer ADCs, VEGF Inhibitors, And Immunotherapy
Don S. Dizon, MD, FACP, FASCO
Controversies In The Management Of Ovarian Cancer A Focus On First Line Treatment
Alexander B. Olawaiye, MD, FRCOG, FACOG, FACS
Advances in the Treatment of High Risk Early Stage Hormone Receptor Positive Breast Cancer
William J. Gradishar, MD, FASCO, FACP
